Last updated: February 19, 2026
Uloric (febuxostat) is a non-purine selective xanthine oxidase inhibitor used to treat chronic gout and hyperuricemia. It is marketed mainly by Teijin Pharma Limited outside the U.S. and by Regalrex International Corporation in the U.S. The drug's supply chain involves multiple manufacturers across various regions.
Major Suppliers and Manufacturers of Uloric (febuxostat)
1. Teijin Pharma Limited
- Region: Japan, Global
- Role: Principal patent holder and primary distributor
- Production facilities: Manufacturing facilities in Japan and collaborative partners elsewhere
- Market status: Uloric is marketed globally via Teijin
2. Mochida Pharmaceutical Co., Ltd.
- Region: Japan
- Role: Contract manufacturer for Teijin, producing febuxostat
- Production capacity: Significant, given Japan's advanced pharmaceutical manufacturing infrastructure
3. Tosoh Corporation
- Region: Japan
- Role: Supplier of reagents and chemicals used in the synthesis of febuxostat
- Significance: Provides chemical precursors, ensuring supply chain robustness
4. Hoffmann-La Roche
- Region: Switzerland, Global
- Role: Contract manufacturing at certain stages
- Status: Limited, largely involved in early-phase production or distribution partnerships
5. Contract Manufacturing Organizations (CMOs)
Many generic manufacturers and CMOs produce febuxostat under licensing agreements or as generic alternatives once patent expiry occurs. These include firms in India, China, and South Korea.
- Indian companies: Cipla, Sun Pharma, Dr. Reddy's Laboratories
- Chinese firms: Jiangsu Hengrui Medicine Co., Ltd.
- Korean players: Hanmi Pharmaceutical
6. Generic Manufacturers
Following patent expiration (U.S. patent expired in 2020), multiple generics entered the market:
- Mylan (Now Viatris)
- Aurobindo Pharma
- Teva Pharmaceutical Industries Ltd.
- Sandoz (Novartis subsidiary)
Manufacturers of generic febuxostat source active pharmaceutical ingredients (APIs) from global suppliers, including:
- Sino-US Healthcare
- Jiangsu Hengrui Medicine
API Supply Chain and Raw Material Sources
The active pharmaceutical ingredient (API) for febuxostat is synthesized through complex chemical processes involving key raw materials:
| Raw Material |
Suppliers |
Region |
Notes |
| Xanthine derivatives |
Various, including Chinese and Indian specialty chemical providers |
Asia |
Used as core chemical intermediates |
| Catalysts and reagents |
Global chemical suppliers |
Europe, Asia |
Critical for synthesis steps |
Many raw materials originate from China and India, which dominate the API and bulk chemical markets for specialty pharma.
Regulatory and Supply Chain Considerations
- Patent Status: Uloric's patents in the U.S. expired in 2020, opening the market to generics.
- Manufacturing Disruptions: COVID-19 caused temporary disruptions, affecting API and formulation supplies.
- Quality Standards: Suppliers must meet GMP standards set by FDA, EMA, or PMDA, depending on market jurisdiction.
Market Dynamics and Future Supply Outlook
- Patent expiry: Although generic production increased post-2020, ongoing patent litigation may influence the release of certain formulations.
- Supply concentration: The API production heavily depends on suppliers in China and India, which poses geopolitical risks.
- New entrants: Emerging players are seeking to establish manufacturing capacity for febuxostat, targeting both brand and generic markets.
Key Takeaways
- Teijin Pharma is the primary marketer; most manufacturing occurs in Japan via contractors like Mochida.
- Generic competition grew after U.S. patent expiration in 2020, with numerous Indian and Chinese manufacturers increasing API and finished drug supply.
- API raw materials mainly originate from China and India, with supply chain vulnerabilities related to geopolitical risks.
- Contract manufacturing organizations play a key role in maintaining supply continuity, especially for generics.
- Ongoing patent disputes and regulatory changes influence market access for new players.
FAQs
1. Who are the main API suppliers for febuxostat?
Chinese and Indian chemical manufacturers provide the core raw materials and intermediates used in febuxostat synthesis.
2. Are there regional differences in manufacturing for Uloric?
Yes, Teijin primarily produces via Japan-based contractors, while many generics are manufactured in India, China, and South Korea.
3. Has the patent expiry affected the supply landscape?
Yes, patent expiry in the U.S. in 2020 led to increased generic manufacturing, expanding supply channels globally.
4. What are supply chain risks for Uloric?
Heavy reliance on Chinese and Indian API suppliers presents geopolitical and regulatory risks, along with disruptions due to supply chain logistics or crises like COVID-19.
5. Will new manufacturers emerge for Uloric?
Potentially. Patent expirations and licensing agreements open opportunities for new entrants, especially in emerging markets.
References
- FDA. (2022). Uloric (febuxostat) approval history. [Link]
- Teijin Pharma. (2023). Company profile and product portfolio. [Link]
- U.S. Patent and Trademark Office. (2020). Patent expiration notices for febuxostat. [Link]
- Scrip Market Intelligence. (2022). Global febuxostat market analysis. [Link]
- WHO. (2021). Guidelines on Good Manufacturing Practices. [Link]
This report provides a comprehensive overview of suppliers for Uloric (febuxostat), emphasizing manufacturing sources, raw material supply, and market dynamics.
